United Kingdom · Question · Written question
UIN 10377
Vitiligo: Ruxolitinib
Introduced
21 October 2024
Last action
29 October 2024 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
29 October 2024
Summary
To ask the Secretary of State for Health and Social Care, whether he plans to review the National Institute for Health and Care Excellence's decision not to recommend Ruxolitinib for use within NHS England for the treatment of vitiligo.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
21 October 2024
Written question
To ask the Secretary of State for Health and Social Care, whether he plans to review the National Institute for Health and Care Excellence's decision not to recommend Ruxolitinib for use within NHS England for the treatment of vitiligo.
Source: Commons
29 October 2024
Answer
The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on whether ruxolitinib should be routinely funded by the NHS, based on an assessment of its costs and benefits.The NICE was unfor...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2024-10-21/10377
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1735945
- uk · wq-1735945 · source updated 29 October 2024